Relapsing-remitting multiple sclerosis is a type of multiple sclerosis ... MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis ... that primary ...

Patients with multiple sclerosis (MS) most commonly have a relapsing-remitting course followed eventually by a secondary progressive phase. During this latter period, disability relentlessly ...

Multiple sclerosis (MS ... and about 2.9 million people worldwide. There are relapsing-remitting and progressive types of MS, but the course is rarely predictable. Researchers still don’t ...

So we'll go online, and I'll see this relapsing, remitting, and primary progressive and secondary progression. All of those names were derived when we didn't really understand the disease as much ...

Let's talk about how multiple sclerosis impacts cognitive function ... which occurs in both relapsing MS and in the progressive forms of MS can perpetuate depression, and that brain fog, slowing ...

Multiple sclerosis (MS ... defined according to clinical characteristics; namely: Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), and Progressive ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

(2:34) A team of Italian investigators recently used magnetic resonance imaging to classify the cognitive features of multiple sclerosis patients into 5 distinct phenotypes, possibly opening the ...

People with multiple sclerosis (MS ... new symptoms occurring either in discrete attacks (relapsing forms) or slowly accumulating over time (progressive forms). Between attacks, symptoms may ...

Multiple Sclerosis (MS) is an autoimmune ... Progressive MS: Previously, progressive forms of MS were divided into Secondary Progressive – arising from prior Relapsing MS – and Primary Progressive – ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...